Patient description: The patient is a 20 year old Caucasian female presents to the clinic with one-sided vision lost and facial weakness, dysarthria and numbness lasting for 1 day. She visited her PCP and underwent brain MRI which revealed a single plaque in the brainstem. After few months, she experienced lower extremities weakness led to balance problem. The second MRI revealed another lesion in the left cerebral hemisphere. The diagnosis of Relapsing Remitting Multiple Sclerosis (RRMS) is confirmed after the second MRI. Her past surgical history is significant for a C-section 2 years ago and she has a one child. She is divorced and is not currently in any sexual relationship. She smokes 10 cigarettes per day and drinks alcohol occasionally. She is working as an editor in a publisher company and she is happy that she can keep working from home most of the time. She is under the treatment of RRMS from 7 months ago.

Clinical trial eligibility criteria: eligible ages (years): 12.0-99.0,  Central Nervous System Disease Multiple Sclerosis (for participation in the whole protocol): 1. Presentation with a clinical syndrome consistent with immune-mediated CNS disorder and/or 2. Neuroimaging evidence of inflammatory and/or demyelinating/ dysmyelinating CNS disease 3. At least 12 years old at the time of enrollment 4. Adults: Able to give informed consent on their own or via a Legally Authorized Representative (LAR) or Durable Power of attorney (DPA), or Minors: parent or legal guardian able to give consent, with child willing to give assent, if reasonable based on their age and assent capacity, able to give assent with consent given by their parent or legal guardian 5. Able to undergo the required procedures, including LP, MRI and clinical/functional evalautions. 1. At least 18 years old at the time of enrollment 2. Vital signs are found within normal range at the time of the screening visit 3. Able to give informed consent 4. Able to undergo related research procedures, such as blood draw, LP for processing of collected biological samples: 1. Presentation with a clinical syndrome consistent with immune-mediated CNS disorder and/or 2. Neuroimaging evidence of inflammatory and/or demyelinating/ dysmyelinating CNS disease 3. Ability to obtain either direct or surrogate informed consent for sample processing and storage  (for participation in the whole protocol): 1. Significant medical condition that would make participation in diagnostic and research part of evaluation impossible or risky 2. Medical contraindications for MRI (ie any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed) 3. Unable to provide informed consent 4. Unwilling to consent for collection of biological samples or their cryopreservation Systemic inflammatory disorder or inflammatory or non-inflammatory nurological diseases. 2. Previous or current history of alcohol and substance abuse 3. Medical contraindications for MRI (i.e. any non-organic implant or other device such as a cardiac pacemaker or infusion pump or other metallic implants, objects or body piercings that cannot be removed) 4. Medical contraindication for LP 5. Psychological contraindications for MRI (i.e. claustrophobia). This will be assessed at the time the medical history is collected. 6. Pregnancy or current breastfeeding 7. Any contraindications to having study procedures done<TAB> 8. History of auditory disorder (i.e. hearing impairment, known impaired acoustic reflex, tinnitus) SUB STUDY TO DATA FOR THE APPS: 1. Because this sub study collects no personal identifiable information (PII), there are no inclusion/  2. Participating subjects are self-declared as not having any neurological deficit, which would be the same population that would provide normative data if the apps were freely available via App store